Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] is delighted to share the news that they have welcomed Patrick Doody aboard as their new Vice President, General Counsel, and Member of their Board of Directors. This esteemed new addition to the team brings extensive experience and knowledge to the Company, and presents an exciting opportunity for the organisation to continue building on its success.
After more than 30 years of representing Nymox and its predecessor company in intellectual property matters, Stephen Doody has recently been appointed to Nymox’s Senior Counsel. This highly experienced and knowledgeable patent attorney specializes in post-grant proceedings, patent infringement litigation, patent prosecution, licensing, opinions, and counseling.
Doody holds a Bachelor of Science in Chemical Engineering from Virginia Tech, a law degree from the Scalia School of Law (formerly George Mason School of Law), and is a former patent examiner, former in-house counsel for Union Carbide Corporation, and former partner at Tier 1, AMLAW 100 firms. He has received Band 2 rankings from Chambers for Intellectual Property and AV rankings from Martindale Hubbell.
In addition to this, Doody is also an adjunct professor of patent law at the George Washington University School of Law, and has served in several leadership positions in various intellectual property associations. His extensive history working with biotechnology, pharmaceutical, and chemical companies has made him a renowned expert in the field of intellectual property law.
Dr. Paul Averback, CEO and Chairman of Nymox, is delighted to announce the appointment of Patrick to the Company’s Board of Directors. Bringing with him decades of industry and intellectual property legal practice experience, Patrick has a first-rate reputation, coming from prestigious practices such as Pillsbury Winthrop.
In addition to his strong legal expertise, Patrick also understands the intricate biochemical and biomedical aspects of the Company’s work, making him an ideal addition to both the management and Board. His real-world knowledge of industry will be a tremendous boon to the Company.
Nymox is taking an important step forward in the effort to help men suffering from benign prostatic hyperplasia (BPH), as it is submitting applications for a groundbreaking, first-in-class drug, NYMOXARFEX. This new treatment, if approved, will offer invaluable relief from symptoms of BPH, without the multitude of problems associated with current medications.
These include intolerable side-effects which can lead to sexual problems, such as impotence and retrograde ejaculation, and an increased risk of prostate cancer, depression and gynecomastia. Surgery, although often successful, is not without its own issues, such as discomforts and permanent retrograde ejaculation in some patients. Nymox is looking to decrease the burden for those affected by this common condition.
About NYMOZARFEX (TM) (Fexapotide)
Introducing Fexapotide (TM), a revolutionary new in-office procedure that offers patients an efficient, safe, and effective solution to BPH. With over 1750 patients and 1600 injections administered in clinical trials, significant long-term improvements have been achieved without the common side effects associated with most BPH treatments. This fast and simple procedure requires no anesthesia or analgesia and can be completed in just minutes.